Results 121 to 130 of about 57,089 (325)

TRPM3 activation causes CGRP release in trigeminal neurons: Implications for migraine mechanisms

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Background The transient receptor potential melastatin 3 (TRPM3) ion channel has been implicated in sensory modulation and pain transmission and may contribute to migraine pathophysiology through calcitonin gene‐related peptide (CGRP) release in the trigeminovascular system. This study aimed to investigate TRPM3 activation and its role in CGRP
Philip V. Reducha   +9 more
wiley   +1 more source

Corrigendum to “TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain” [Biochem. Pharmacol. 192 (2021) 114688]

open access: green, 2021
Moses M. Kasembeli   +8 more
openalex   +2 more sources

Metabotropic glutamate receptor 2/3 (mGluR2/3) activation suppresses TRPV1 sensitization in mouse, but not human sensory neurons [PDF]

open access: yes, 2018
The use of human tissue to validate putative analgesic targets identified in rodents is a promising strategy for improving the historically poor translational record of preclinical pain research.
Baranger, David A.A.   +5 more
core   +2 more sources

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective/Background This study was undertaken to assess participants' impression of use and satisfaction with STS101 in a long‐term, open‐label safety study. The ASCEND study assessed the safety and tolerability of STS101, an investigational drug–device combination of 5.2 mg dihydroergotamine in a single‐use nasal delivery device for the ...
Jessica Ailani   +4 more
wiley   +1 more source

Perturbations in neuroinflammatory pathways are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors. [PDF]

open access: yes, 2019
Paclitaxel is a common chemotherapy drug associated with the development of chronic paclitaxel-induced peripheral neuropathy (PIPN). PIPN is associated with neuroinflammatory mechanisms in pre-clinical studies.
Abrams, Gary   +9 more
core  

Chinook winds and migraine attack onset in children and adolescents: A prospective longitudinal clinical cohort study

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
ABSTRACT Objective To explore the relationship between migraine attack onset in children and adolescents and Chinooks, which are dry and warm westerly winds that generally occur in the winter and bring about abrupt weather changes to the east of the Rocky Mountains in Southern Alberta, Canada. Methods This was a prospective longitudinal clinical cohort
Rylan Heart Villaruz   +6 more
wiley   +1 more source

Psychosocial factors as predictors of headache chronification: A systematic review and meta‐analysis of longitudinal studies

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This study aimed to systematically review the literature and summarize, as well as quantitatively pool when feasible, longitudinal evidence regarding psychosocial predictors of headache chronification. Methods A comprehensive search was conducted in PubMed/MEDLINE, CINAHL, and PsycInfo.
Cornel H. M. Tol   +4 more
wiley   +1 more source

Dim Light at Night Exposure Induces Cold Hyperalgesia and Mechanical Allodynia in Male Mice

open access: green, 2020
Jacob R. Bumgarner   +4 more
openalex   +2 more sources

OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open‐Label (COMPEL) trial

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Examine treatment responses to and safety of onabotulinumtoxinA for the preventive treatment of chronic migraine (CM) among diverse racial groups. Background Evidence suggests there are differences in headache treatment patterns, symptom profiles, and burden based on race.
Andrew M. Blumenfeld   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy